Actively Recruiting
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Led by Tango Therapeutics, Inc. · Updated on 2025-11-18
126
Participants Needed
13
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
CONDITIONS
Official Title
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Is 18 years of age or older at the time of signing consent
- Has ECOG performance status of 0 or 1
- Has measurable disease based on RECIST v1.1
- Has documented STK11 mutation in a solid tumor verified by a validated test
- Has confirmed diagnosis of locally advanced or metastatic solid tumor
- Has adequate organ, liver, and renal function based on local lab tests
- Has a negative serum pregnancy test at screening
- Has provided written informed consent according to local guidelines
You will not qualify if you...
- Known allergy or intolerance to TNG260, PD-1 antibody, or their ingredients
- Uncontrolled illness limiting study compliance
- Active infection needing systemic therapy
- Participating in or planning to participate in another investigational study
- Gastrointestinal issues that could affect oral TNG260 absorption
- Active prior or current other malignancy
- CNS metastases with worsening neurological symptoms
- Active liver disease
- Clinically significant heart disease
- Pregnant or breastfeeding female patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
UCLA Hematology/Oncology
Santa Monica, California, United States, 90404
Actively Recruiting
2
SCRI at HealthOne
Denver, Colorado, United States, 80218
Actively Recruiting
3
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
4
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
5
Henry Ford Health System
Detroit, Michigan, United States, 48202
Actively Recruiting
6
START MidWest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
7
NYU Langone Hematology Oncology Associates-Mineola
Mineola, New York, United States, 11501
Actively Recruiting
8
New York University Langone Health
New York, New York, United States, 10016
Actively Recruiting
9
Sarah Cannon Tennessee Oncology
Nashville, Tennessee, United States, 37203
Actively Recruiting
10
US Oncology Investigational Products Center
Dallas, Texas, United States, 75246
Actively Recruiting
11
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
12
NEXT Oncology Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
13
US Oncology Investigational Products Center
Norfolk, Virginia, United States, 23502
Actively Recruiting
Research Team
A
Adam Crystal, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here